Publications

Journal articles and chapters in books

Neurosurgery

  1. With Prof. D. Parkinson: Hydrocephalus-A shunt between ventricles and Stenson's Duct. Canad J Surg 4:183-185,1961.
  2. With Prof. D. Parkinson: Saccular Aneurysm of the Ophthalmic Artery. Canad J Surg 4:229-232,1961.
  3. Mechanism of Rupture of Intracranial Saccular Aneurysms. Surgery 54:347-350,1963
  4. Partial Carotid Occlusion as Treatment of Intracranial Internal Carotid Aneurysms. Canad Med Assoc J 88:245-251,1963.
  5. With Dr. R. Ojemann: Carotid Blood Flow in Paget's Disease of the skull-A study with electromagnetic flowmeter. J Neurosurg 20:471-473,1963.
  6. Aberrant Roots of the Abducent nerve. J Neurosurg 21:349-351.
  7. Some Observations on the Anatomy of the Middle Cerebral Artery. Canad J Surg 7:134-137,1964.
  8. Surgery of Intracranial Berry Aneurysms. Canad J Surg 8:172-187,1965.
  9. Intraventricular Cavernous Hemangioma of the Lateral Ventricle. J Neurosurg 24:762-764,1966.
  10. Headache in relation to intracranial aneurysm. Headache 7:122-126,1967.
  11. Congenital anomaly of the cervical spine simulating fracture dislocation. J Canad Assoc Radiol 19:329,1967.
  12. Chronic benign thrombosis of the superior sagittal sinus. J Canad Assoc Radiol 20:39,1968.
  13. With Dr. Posner: An unusual case of severe burns, meningitis, obstructive hydrocephalus and neuroblastoma in a child under age two. Clin Ped 7:283-288,1968.
  14. Total visualization of the intracranial arterial circulation following unilateral carotid angiography in a patient with ruptured posterior cerebral aneurysm. Am J Roent 104:83-85,1968.
  15. Recurrence of existed cavernous hemangioma in the opposite cerebral hemisphere. J Neurosurg 33:453-456,1968.
  16. Saccular aneurysm of the ophthalmic artery. Am J Ophthalmol 69:997-998,1970.
  17. Doctor's status in the community. Canadian Doctor, Feb.1970, p.66.
  18. Diagnosis of extradural hematoma by brain scan. Canad M Assoc J 107:218-219,1972.
  19. Glimpses of neurosurgery in the People's Republic of China. International Surgery 57:155-158,1972.
  20. Aneurysms of the vertebral-basilar system. Proceedings of the 3rd Canadian Congress of Neurological Sciences, 1968. Book of Abstracts, p24.
  21. Glimpses of Chinese Medicine. Canad Med Assoc J 106:46-50,1972.
  22. Reoperative Surgery for Lumbar Disc Protrusions. International Surgery 59:106,1974.
  23. Surgery of Intact Intracranial Aneurysms. J Neurosurg 40:495-498,1974.
  24. Surgery of Anterior Communicating Aneurysms. Surg Neurol 2:31-33,1974.
  25. Familial Intracranial Aneurysms. Acta Neurochir 30:129-137,1974.
  26. Sciatica and herpes simplex. J Neurosurg 41:518,1974.
  27. Use of Diazepam in cerebral angiography. Canadian J Neurol Sci 1:141-142,1974.
  28. Anterior approach to the cervical spine. Canad Med Assoc Journal 111:49-50,1974.
  29. Evaluation of a surgeon's competence. Modern Medicine of Canada 29:7-8,1974.
  30. Nerve root scarring as a complication of lumbar disc surgery. Neurochirurgia 17:185-192,1974.
  31. Acupuncture and the neurosurgeon. Am J Acupuncture 2:164-166,1974.
  32. Reoperative surgery on patients with lumber disc surgery. International Surgery 60:29-32,1975.
  33. Neurosurgery at SCT Medical Center, India. Kerala Medical Journal 16:67-69,1976.
  34. Management of neurosurgical emergencies. Kerala Medical Journal 16:67-69,1976.
  35. Are your peers what they appear to be? Canadian Doctor, August 1975,p.58-60.
  36. With Prof. MG Yasargil: Arteriovenous malformations of the splenium of the corpus callosum--microsurgical treatment. Surg Neurol 5:5-14,1976.
  37. With Prof. MG Yasargil: Arteriovenous malformations of the anterior and middle portions of the corpus callosum--microsurgical treatment. Surg Neurol 5:67-80,1976.
  38. With Prof. MG Yasargil: Frontolateral pterion approach to the basilar bifurcation Aneurysms. Surg Neurol 6:83-91,1976.
  39. With Prof. MG Yasargil: Arteriovenous malformations of the vein of Galen. Microsurgical treatment. Surg Neurol 6:195-200,1976.
  40. With Prof. MG Yasargil: Anatomy of the subarachnoid cisterns of the brain. J Neurosurg 44:298-302,1976.
  41. With Prof. K-H. Holbach: Differentiation between reversible and irreversible post-stroke changes in the brain tissue and its relevance to cerebrovascular surgery. Surg Neurol 7:324-331,1977.
  42. Practice of Medicine in Shiraz (Iran). World Medicine, 8 Feb 1978,p.19-22.
  43. Repair of small blood vessels with Nd:YAG laser. Surgery 85:684-688,1979.
  44. Microvascular repair with Nd:YAG laser. Acta Neurochir Supp 28:260-262,1979.
  45. Sutureless microvascular anastomosis using Nd:YAG laser. J Microsurgery 1:436-439,1980.
  46. Surgical treatment of unruptured intracranial aneurysms. Acta Neurochir 66:187-194,1982.
  47. Photocoagulation of cerebral arteriovenous malformations and arterial aneurysms with Nd:YAG laser. Neurosurgery 13:374,1982.
  48. Pitfalls in the diagnosis of intracranial aneurysms. American Family Physician 27:139-144,1983.
  49. Lasers in neurosurgery--A review. Laser in Surg & Med 2:217-230,1983.
  50. Sutureless end-to-side microvascular anastomosis with Nd:YAG laser. Vasc. Surg 17:240-243, 1983.
  51. Nahtlose End-zu-Seite mikrovaskulare Anastomose mit Nd:YAG laser (German). In Staeler G, Hoffstetter A(eds): Verhandlungsbericht Deutsche Gesellschaft f�ermedizin, W. Zuckerschwerdt Verlag, M�, 1983:69-72.
  52. Der Laser in der Neurochirurgie. Fortschr Med 101:1930-1934,1983.
  53. Nd:YAG Laser in Microneurosurgery. In, Jaffe SN (ed): Nd:YAG Laser in Medicine and Surgery. Elsevier Publishing Company, New York,1983:131-140.
  54. With Prof. H. Wassmann: Cerebral protection during carotid endarterectomy. Acta Neurochir 71:99-108,1984.
  55. Role of Laser in Microvascular Surgery. In Proceedings of ICALEO'83, Vol 37. Laser Institute of America, Toledo, Ohio, 1984:90-93.
  56. Current status of laser application in neurosurgery. IEEE Journal of Quantum Electronics 20:1401-1406,1984.
  57. Sutureless extra-intracranial anastomosis using Nd:YAG laser-clinical application. Lancet ii:816-817,1984.
  58. Lasers in neurological surgery. J Neurosurg 60:872,1984.
  59. Laser surgery. JAMA 251:2349,1984.
  60. Complications of Nd:YAG laser application in neurosurgery. Neurosurgery 16:759-762, 1985.
  61. Incision of the brain with varipulse carbon dioxide laser. Neurosurgery 18:762-765, 1986.
  62. With B. Fischer: Improvement of information processing ability of the brain and of the fluid intelligence by brain jogging. Geriatrics, pregeriatrics and rehabilitation 2(2):42-54,1986.
  63. CO2 laser provides safe, complete excision of difficult brain tumors. Laser Practice Report 3(1):1s-2s,1987.
  64. Sutureless Microvascular Anastomosis with Nd:YAG Laser. J Neurosurg 68:829,1988.
  65. Anastomosis extra-intracranial sin sutura utilizando el laser Nd:YAG. Experiencia clinica (Spanish). Investigacion Y Clinica Laser 4:50-53,1987.
  66. Quackery and Health Frauds against the Elderly. Geriatric Pregeriatrics and Rehabilitation 3:106-108,1987.
  67. Mentaltraining: Grundlegende Prinzipien und Anwendungen (in German). Natur- und Ganzheits Medizin 2:45-48,1988.
  68. With B. Fischer: Diagnostic steps of dementia in the commentary by C.G. Gottfries. Alzheimer Dis Assoc Disord 1989 Winter;3(4):228-30.

Hyperbaric medicine

  1. Jain KK, Fischer B: New Aspects of the use of Hyperbaric Oxygenation for Rehabilitation of Stroke Patients. Geriatrics and Rehabilitation 1:45-46,1988.
  2. With B. Fischer: Clinical, biochemical and mental changes during hyperbaric oxygen therapy. Proceedings of the First Swiss Symposium on Hyperbaric Medicine, Basel, 1986. pp.256-278.
  3. With B. Fischer: Effect of Hyperbaric Oxygen Therapy on Migraine Headaches. XIII Annual Meeting of EUBS on Diving and Hyperbaric Medicine, Palermo, Italy, September 9-12, 1987(Abstract).
  4. With B. Fischer: Blood lactate and ammonia levels during exercise under hyperbaric oxygenation. Proc XIII Annual EUBS Meeting, Palermo Italy. Marroni A and Oriani G (eds). 1987:123-125.
  5. With B. Fischer: Role of Hyperbaric Oxygen Therapy in Geriatrics. In Abstracts, Romanian Journal of Geriatrics and Gerontology, Supplement to No.1, Vol 9, 1988. Bucharest, Romania.
  6. Exercise Therapy for Stroke Patients under Hyperbaric Oxygenation Presented at the 7th International Symposium ADAPTED PHYSICAL ACTIVITY. Berlin, 21-24 June, 1989. Published in volume of abstracts, page 107-108.
  7. Effect of Hyperbaric Oxygen on spasticity in stroke patients. Journal of Hyperbaric Medicine 4:55-61,1989.
  8. Effectiveness of Hyperbaric oxygen in stroke rehabilitation. In Bakker DJ, Schmutz J (eds): Proceedings of the Second Swiss Symposium on Hyperbaric Medicine, Basel, Foundation for Hyperbaric Medicine, 1990, pp.341-345.
  9. With Dr. S. Gottlieb: Hyperbaric Therapy -- A critical evaluation. Fort Lauderdale, Florida. American College of Hyperbaric Medicine, 1990:1-186.
  10. Hyperbaric oxygen and combat casualty care (letter). Military Medicine 155:A10,1990.
  11. High pressure neurological syndrome (HPNS). Acta Neurologica Scandinavica 1994;90:45-50.
  12. Hyperbaric oxygen therapy. N Engl J Med 1996;335:1684.
  13. Hyperbaric oxygen therapy in acute stroke. Stroke 2003 September;34:e153.

Biopharmaceutical topics

  1. Association of low circulating thyroid hormones with carbamazepine therapy. J Pharmaceutical Med 1;239-253:1991
  2. Lupus erythematosus like syndromes associated with carbamazepine therapy. Drug Safety 6;350-360:1991
  3. Investigation and management of loss of efficacy of an antiepileptic medication using carbamazepine as an example. J Roy Soc Med 1993;86:133-136.
  4. With Dr. J. Bem. Classification of causality of adverse drug reactions. J Pharmaceutical Med 2;101-107:1993.
  5. Drug-induced cutaneous vasculitis. Adv Drug React & Toxicol Rev 12:263-276,1993.
  6. Cutaneous vasculitis associated with granulocyte colony-stimulating factor. J Am Acad Dermatol 1994;31:213-215.
  7. A short practical method for triage of adverse drug reactions. Drug Information Journal 1995;29:339-342.
  8. Swiss embrace complementary medicine. Nature Medicine 1995;1:107.
  9. Sweet's syndrome associated with granulocyte colony-stimulating factor. CUTIS 1996;57:107-110.
  10. Molecular genetic profiling for diagnostics and clinical trials. Drug Discovery Today 1997;2:310-311.
  11. Strategies and technologies for drug delivery systems. Trends in Pharmacological Sciences 1998;19:155-157.
  12. Pharmacotherapy of chronic venous insufficiency: a critical review. Journal of Drug Assessment 1998;1:269-288.
  13. Effect of oxerutins on venous endothelium: its relevance to pharmacotherapy of CVI. International Angiology 1999;18 (Suppl 1):6-11.
  14. Functional Genomics: strategies and enabling technologies for target and drug discovery. Drug Discovery Today 1999;4:50-53.
  15. Advances in Molecular Labels, Signaling and Detection: enhancing sensitivity, accuracy and speed. Drug Discovery Today 1999;4: 346-349.
  16. Emerging therapeutic targets for glioblastoma multiforme. Emerging Therapeutic Targets 1999;3(4):613-627.
  17. Nicaraven for the treatment of cerebral vasospasm in subarachnoid haemorrhage. Exp Opin Invest Drugs 2000;9:859-870.
  18. Neuroprotective therapy for stroke. Exp Opin Invest Drugs 2000;9:695-711.
  19. An assessment of rufinamide as an antiepileptic in comparison with other drugs in clinical development. Exp Opin Invest Drugs 2000;9:829-840.
  20. Biotechnological applications of lab-chips and microarrays. Trends in Biotechnology 2000;18:278-280.
  21. An evaluation of mitoxantrone for the management of multiple sclerosis. Exp Opin Invest Drugs 2000;9:1139-1149.
  22. Applications of biochip and microarrays systems in pharmacogenomics. Pharmacogenomics 2000;1(3):289-307.
  23. An evaluation of levetirecetam in the management of epilepsy. Exp Opin Invest Drugs 2000;9:1611-1624.
  24. An evaluation of memantine in the management of dementia. Exp Opin Invest Drugs 2000;9:1397-1406.
  25. An evaluation of zonisamide in the management of epilepsy. Exp Opin Invest Drugs 2000;1:1245-1260.
  26. Transforming innovation and commercialization in drug discovery. Drug Discovery Today. 2000;5:318-320.
  27. A guide to drug evaluation for chronic pain. Emerging Drugs: The Prospect for Improved Medicines. 2000;1:241-257.
  28. An evaluation of intrathecal ziconotide for the treatment of chronic pain. Exp Opin Invest Drugs 2000;9:2403-2410.
  29. An evaluation of iloperidone for the treatment of schizophrenia. Exp Opin Invest Drugs 2000;9:2935-2943.
  30. Evaluation of intravenous parecoxib for the relief of acute postsurgical pain. Exp Opin Invest Drugs 2000;9:2717-2723.
  31. Applications of proteomics in oncology. Pharmacogenomics 2000;1:385-393.
  32. Bacteria as anticancer agents. Expert Opinions in Biological Therapies 2001;1:291-300.
  33. CHI's 3rd Annual Conference: Lab-on-Chip and Microarrays, 22-24 January 2001, Z� Switzerland. Pharmacogenomics 2001;2:73-77.
  34. Genomics for business. Drug Discovery Today 2001;6:131-132.
  35. With Eric Jain: Integrated Bioinformatics - high-throughput interpretation of pathways and biology. Trends in Biotechnology 2001;19:157-158.
  36. More clinical input required for R&D decision-making? Drug Discovery Today 2001;6:175-176.
  37. Proteomics: new technologies and their applications. Drug Discovery Today 2001, 6:457-459.
  38. Applied neurogenomics. Pharmacogenomics 2001;2:143-153.
  39. In the pipeline: new antipsychotics. Clinical Researcher 2001;5:12-18.
  40. Proteomics: delivering new routes to drug discovery - part I. Drug Discovery Today 2001 Aug 1;6:772-774.
  41. Proteomics: delivering new routes to drug discovery - part II. Drug Discovery Today 2001 Aug 15;6: 829-832.
  42. Will neurogenomics revolutionalize neurotherapeutics? (editorial). Expert Rev Neurotherapeutics 1:89-91, 2001.
  43. Biochips for gene spotting. Science 294:621-623, 2001.
  44. Post-genomic applications of lab-on-a-chip and microarrays. Trends in Biotechnology 2002;5:184-185.
  45. Application of Laser Capture Microdissection to Proteomics. Methods in Enzymology 2002;356:157-167.
  46. Recent advances in oncoproteomics. Current Opinion in Molecular Therapeutics. 2002;4:203-209.
  47. Using proteomics to identify targets and leads. Trends in Biotechnology 2002;20:319-320.
  48. From Molecular diagnostics to personalized medicine. Expert Rev Med Diagn 2002;2:89-91.
  49. The role of protein chip technology in molecular diagnostics. IVD Technology 2002 July/August;8:49-56.
  50. Proteomics 2002. Drug Discovery Today 2002;7:900-902.
  51. Role of proteomics in diagnosis of cancer. Techn Cancer Res & Dev 2002;1:281-286.
  52. Proteomics-based anticancer drug discovery and development. Techn Cancer Res & Dev 2002;1:231-236.
  53. Oncoproteomic State-of-the-Art (editorial). Techn Cancer Res & Dev 2002;1:219-220.
  54. Role of Neuroproteomics in CNS Drug Discovery. Targets 2002;1:95-101.
  55. The Neurobiology and Neuropharmacology of Alzheimer's Disease: Roads to Treatment Strategies. ASPET-Ray Fuller Symposium, 20-24 April 2002, New Orleans, LA, USA. ID Weekly Highlights, Current Drugs Ltd, May 2002.
  56. Angiogenesis in brain tumors. In, Black PM & Loeffler J (eds) Cancer of the Nervous System, 2nd ed. Lippincott, Williams & Wilkins, Philadelphia, 2005:761-778.
  57. Stem Cell Technologies in Regenerative Medicine. Exp Opin Biol Ther 2002;2:771-773
  58. Ethical and regulatory aspects of embryonic stem cell research. Exp Opin Biol Ther 2002;2:819-826
  59. Current trends in molecular diagnostics. Medical Device Technology 2002;13:14-18
  60. Personalised medicine. Curr Opinion Mol Ther 2002;4:548-558
  61. Nanodiagnostics:application of nanotechnology in molecular diagnostics. Expert Rev Mol Diagn 2003;4:153-161
  62. Lab-on-a-Chip and Microarrays:Discovery and Development. Pharmacogenomics 2003;4:123-125
  63. Current trends in molecular nanosensors. Medical Device Technology 2003;14:10-15
  64. Proteomics and Drug Discovery, Chapter 20 in "Proteomics in Nephrology", Contributions to Nephrology,Vol 141,Karger, 2003:308-327
  65. Proteomics and Protein Arrays Europa: IIR Conference, Copenhagen, 16-18 June 2003. Pharmacogenomics 2003 July;4:383-385
  66. Proteomics for Drug Target and Biomarker Identification: IBC Conference, Basel, 30 June-2 July 2003. Targets 2003 October;2:189-190
  67. Information on commercial aspects of pharmacogenomics. Pharmacogenomics 2003;4:801-803
  68. Modulators of nicotinic acetylcholine receptors as analgesics. Curr Opinion Invest Drugs 2004;5:76-81.
  69. Application of Proteomic Technologies for Drug Discovery, Chapter 9 in, Hondermark H (ed) Proteomics: Biomedical and Pharmaceutical Applications, Kluwer Academic, The Netherlands, 2004:201-228
  70. Proteomics-based Anticancer Drug Discovery. In, LaRochelle WJ (ed) The Oncogenomics Handbook. The Humana Press, Totowa, USA, 2005:123-134.
  71. Applications of Biochips: from Diagnostics to Personalized Medicine. Current Opinion in Drug Discovery and Development 2004;7:285-9.
  72. RNAi and siRNA in Target Validation. Drug Discovery Today 2004;9:307-9.
  73. RNAi and siRNA - BioTrends Conference 2004. Pharmacogenomics 2004;5:5:331-6.
  74. Role of Pharmacoproteomics in the Development of Personalized Medicine. Pharmacogenomics 2004;5:239-42.
  75. Current Status of Fluorescent In Situ Hybridization. Medical Device Technology 2004 May:14-17.
  76. Role of oncoproteomics in the personalized management of cancer. Expert Rev Proteomics 2004;1:89-95.
  77. Nanotechnology-based Lab-on-a-Chip Devices. In, Encyclopedia of Diagnostic Genomics and Proteomics, Marcel Dekkar Inc, New York, 2005:891-895.
  78. Personalized Medicine. In, Encyclopedia of Diagnostic Genomics and Proteomics, Marcel Dekkar Inc, New York, 2005:994-999.
  79. Proteomic Technologies for Cancer Target Validation. Drug Discovery Today-Technologies. 2004;1:75-78.
  80. Ethical and regulatory aspects of embryonic stem cell research. Expert Opin Biol Ther 2005;5:153-162.
  81. Nanotechnology in Clinical Laboratory Diagnostics. Clinica Chimica Acta 2005;358:37-54.
  82. Personalised Medicine for Cancer - From Drug Development into Clinical Practice. Exp Opinion Pharmacotherapy 2005;6:1463-76).
  83. Nanotechnology-based Drug Delivery for Cancer. Technology in Cancer Research & Treatment 2005;4:407-416.
  84. Drug Delivery for Cancer (editorial). Technology in Cancer Research & Treatment 2005;4:311-314.
  85. The role of nanobiotechnology in drug discovery. Drug Discovery Today 2005;10:1435-1442.
  86. Applications of AmpliChip CYP450. Molecular Diagnosis 2005;9:119-127.
  87. Conference Report on Personalized Medicine, IBC 14 Sep 2005, Boston MA. Personalized Medicine 2005 November;2:287-290.
  88. Conference Report on Molecular Diagnostics, IBC 13 Sep 2005, Boston MA. Exp Rev Mol Diagn 2005:847-9.
  89. Role of Nanobiotechnology in Developing Personalized Medicine for Cancer. TCRT 2005;4:645-650.
  90. Applications and commercial potential of RNAi. Conference report RNAi Europe 2005. IDrugs 2005 December;8:982-983.
  91. Personalized Neurology. Personalized Medicine 2005;2:15-21.
  92. What can transcranial magnetic stimulation offer general neurology practice? Practical Neurology 2005;4:34-40.
  93. Nanoparticles as targeting ligands. Trends Biotechnol 2006;24:143-5.
  94. Future prospects for the cure of brain cancer (editorial). TCRT 2006;5:183-184.
  95. Role of nanotechnology in developing new therapies for diseases of the nervous system (editorial). Nanomedicine 2006;1:9-12.
  96. A Critical Review of the Royal Society's Report on Personalized Medicine (editorial). Drug Discovery Today 2006;11:573-575.
  97. Jain KK. Gene Therapy, in Pharmacology, edited by Majewski H, in Encyclopedia of Life Support Systems (EOLSS), Developed under the auspices of the UNESCO. Eolss Publishers, Oxford, UK.
  98. Commercial potential of RNAi. Mol BioSystems 2006:2:523-526.
  99. Impact of Nanotechnology on Healthcare. Nanotechnology Law & Business 2006;3(4):411-418.
  100. Challenges of developing personalized medicines. Current Opinion in Molecular Therapeutics 2006;8:487-492.
  101. Integrative Omics, Pharmacoproteomics, and Human Body Fluids. In, Thongboonkerd V (ed) Proteomics of Human Body Fluids: Principles, Methods, and Applications. Humana Press, Totowa, NJ, 2007:pp 175-192.
  102. Jain KK. Role of Nanobiotechnology in the Development of Nanomedicine. In, Thassu D, et al (eds) Nanoparticulate Drug Delivery Systems. Informa Healthcare, London, 2007:pp 173-183.
  103. Jain KK. Oncoproteomics for Personalized Management of Cancer. In, Daoud SS (ed) Proteomics in Cancer Therapy. Humana Press, Totowa, NJ, 2008:81-99.
  104. Jain KK. Nanomedicine. In, Shoseyov O & Levy I (eds) NanoBioTechnology: BioInspired device and materials of the future. Humana Press, Totowa, NJ, 2008:303-327.
  105. Use of nanoparticles for drug delivery in glioblastoma multiforme. Expert Review of Neurotherapeutics 2007;7:363-372.
  106. Nanobiotechnology-based drug delivery to the central nervous system. Neurodegenerative Dis 2007;4:287-291.
  107. Stability and delivery of RNA via the gastrointestinal tract. Curr Drug Delivery 2008;5:27-31.
  108. Role of nanobiotechnology in drug discovery. In, Guzman CA and Feuerstein G (eds) Pharmaceutical Biotechnology. Landes Press, Austin, Texas, 2009. or Adv Exp Med Biol 2009;655:37-43.
  109. Nanomedicine: application of nanobiotechnology in medical practice. Medical Principles & Practice 2008;17:89-101.
  110. Cancer Biomarkers: current issues and future directions. Curr Opin Mol Ther 2007;9:563-71.
  111. Applications of Nanobiotechnology in Clinical Diagnostics.Clin Chem 2007;53:2002-2009.
  112. Recent advances in clinical oncoproteomics. Journal of BUON 2007;12 (suppl 1):S31-S38.
  113. Drug delivery systems: an overview. In, Jain KK (ed). Drug Delivery Systems. Totowa, NJ, Humana Press, 2008:1-50.
  114. Nanotechnology in drug discovery. In, Seethala R (ed) Handbook of Drug Screening, 2nd edition, Informa, 2009:464-475.
  115. How Will Genomics Affect the Practice of Neurology? Practical Neurology 2007;6:44-51.
  116. Recent advances in nanooncology. TCRT 2008;7:1-13.
  117. Pain Management: Visiongain Fourth Annual Conference, 31 October to 2 November 2007, London UK. IDrugs 2008;11:27-29.
  118. Biotechnology-based Drug Discovery. In, Rapley R (ed) Molecular Biology and Biotechnology, 5th Edition, Royal Society of Chemistry, Cambridge, UK, 2008:307-336.
  119. Personalized Clinical Laboratory Diagnostics. Adv Clin Chem, 2008;47:95-119.
  120. Innovations, Challenges and Future prospects of Oncoproteomics. Molecular Oncology 2008;2:153-160.
  121. Current challenges and future prospects in management of neuropathic pain. Expert Review of Neurotherapeutics 2008;;8:1735-1748.
  122. Gene therapy for pain. Expert Opinion on Biological Therapy. 2008;8:1855-1866.
  123. Cell therapy for pain. Expert Opinion on Biological Therapy. 2008;8:1847-1853.
  124. Neuroprotection in Traumatic Brain Injury. Drug Discovery Today 2008;13:1082-89.
  125. Role of nanobiotechnology in the development of personalized medicine. Nanomed 2009;4:249-52.
  126. Current Status and Future Prospects of Nanoneurology. J Nanoneuroscience 2009;1:56-64.
  127. Cell Therapy for CNS Trauma. Mol Biotechnol 2009;42:367-376.
  128. Application of Nanobiotechnology in Cancer Therapeutics. In, Lu Y, Mahato RI (eds) Pharmaceutical Perspectives of Cancer Therapeutics. Springer, New York, 2009:245-268.
  129. Potential of nanobiotechnology in management of glioblastoma multiforme. In, Ray SK (ed) Glioblastoma: Molecular Mechanisms of Pathogenesis and Current Therapeutic Strategies, Springer, New York, 2010:399-419.
  130. Novel strategies for the treatment of brain cancer. In, Erdmann VA, Reifenberger G, Barciszewski J (eds) Therapeutic Ribonucleic Acids in Brain Tumors, Springer, Heidelberg, 2009:85-102.
  131. An overview of drug delivery to the central nervous system. Neuromethods 2010;45:DOI 10.1007/978-1-60761-529-3_1.
  132. Innovative diagnostic technologies and their significance for personalized medicine. 2010 Mol Diagn Ther;14:141-7.
  133. Personalized cancer vaccines. Expert Opin Biol Ther 2010;12:1637-47.
  134. Integration of biotechnologies for the development of personalized medicine. In, Kayser O and Warzecha H (eds) Pharmaceutical Biotechnology, 2nd ed, John Wiley & Sons, 2010.
  135. Regenerative Therapy for Central Nervous System Trauma. In, Steinhoff G (ed) Regenerative Medicine -- from protocol to patient. Springer, London, 2011:605-625.
  136. Nanobiotechnology. Chapter 68 in, Butler E (ed) Scientific Fundamentals in Biotechnology, Volume 1, Section 6: The biophysical basis. Elsevier, Amsterdam, 2011.
  137. Recent advances in nanooncology. BMC Medicine 2010;8:83.
  138. The Role of Nanobiotechnology in the Development of Personalized Medicine. Med Princ Pract 2011;20:1-3.
  139. Role of Nanobiotechnology in the Personalized Management of Glioblastoma Multiforme. Nanomedicine 2011;6:411-4.
  140. Nanobiotechnology and Personalized Medicine. In, Villaverde A (ed) Nanoparticles in Translational Science and Medicine. Academic Press /Elsevier, 2011.
  141. Role of nanodiagnostics in personalized cancer therapy. Clin Lab Med 2012 (in press).
  142. Role of biological therapies in the development of personalized medicine (invited editorial). Expert Opin Biol Ther 2012;12:1-5.
  143. Synthetic Biology & personalized medicine. Drug Discovery Today 2012 (in preparation)

Contributions to MedLink Neurology

MedLink Corporation, San Diego, California, USA. 1997-current. The 142 articles are part of an electronic encyclopedia of neurology containing 1100 articles by approximately 450 authors, which are updated every year.

Neuropharmacology

  1. Principles of neuropharmacology
  2. Clinical trials and drug development for neurological disorders
  3. Statistics for the neurologists
  4. Drug delivery to the central nervous system
  5. Blood-Brain Barrier
  6. Innovative therapies for cerebral vasospasm
  7. Ion channels and neurological disorders
  8. Chelation therapy in neurological disorders
  9. Vaccination for neurological disorders
  10. Intrathecal therapy

Drugs used for neurological disorders

  1. Alteplase
  2. Anticholinergics
  3. Anticonvulsants
  4. Atomoxetine
  5. Baclofen
  6. Carbamazepine
  7. Citalopram
  8. Clopidogrel
  9. Coenzyme Q10
  10. Dalfampridine
  11. Dihydroergotamine
  12. Diazepam
  13. Donepezil
  14. Entacapone
  15. Fingolimod
  16. Fluoxetine
  17. Fosphenytoin
  18. Gabapentin
  19. Galantamine
  20. Glatiramer
  21. Infliximab
  22. Interferon beta 1a
  23. Interferon beta 1b
  24. Intravenous immune globulin
  25. Lacosamide
  26. Lamotrigine
  27. Levetiracetam
  28. Levodopa
  29. Memantine
  30. Methylphenidate
  31. Mitoxantrone
  32. Mycophenolate
  33. Modafinil
  34. Natalizumab
  35. Nimodipine
  36. Oxcarbazepine
  37. Pemoline
  38. Phenytoin
  39. Pramipexole
  40. Prednisone
  41. Pregabalin
  42. Primidone
  43. Pyridostigmine
  44. Rasagiline
  45. Resperidone
  46. Riluzole
  47. Rivastigmine
  48. Ropinirole
  49. Rotigotine
  50. Selective Serotonin Reuptake Inhibitors
  51. Selegeline
  52. Sodium oxybate
  53. Sumatriptan
  54. Tapentadol
  55. Tiagabine
  56. Tizanidine
  57. Tolcapone
  58. Topiramate
  59. Triptans
  60. Valproic acid
  61. Vigabatrin
  62. Ziconotide
  63. Zonisamide

Neuroprotection, neurotrophic factors and regenerative neurology

  1. Neuroprotection in disorders of the central nervous system
  2. Principles of regeneration and repair in the nervous system
  3. Cell therapy for neural repair and regeneration
  4. Scientific basis of the application of neurotrophic factors in neurological disorders
  5. Application of neurotrophic factors in degenerative neurological disorders
  6. Application of neurotrophic factors in peripheral neuropathies
  7. Application of neurotrophic factors in cerebrovascular disorders
  8. Application of neurotrophic factors in trauma to the nervous system

Gene therapy

  1. Gene therapy for neurological disorders: methods and principles
  2. Gene therapy of neurogenetic disorders
  3. Gene therapy of malignant gliomas
  4. Gene therapy of neurodegenerative disorders
  5. Gene therapy of muscular dystrophy
  6. Gene therapy of cerebrovascular disease

Pharmacotherapy of pain

  1. Overview, physiology, and approach to the management of pain
  2. Pathophysiology and management of chronic pain
  3. Pathophysiology and management of cancer pain
  4. Central neuropathic pain: pathophysiology and pharmacotherapy
  5. Phantom limb pain

Drug-induced Neurological Disorders

  1. Introduction to drug-induced neurological disorders
  2. Drug-induced aseptic meningitis
  3. Drug-induced cerebrovascular disorders
  4. Drug-induced delirium
  5. Drug-induced dementia
  6. Drug-induced disturbances of taste and smell
  7. Drug-induced memory disorders
  8. Drug-induced myopathy
  9. Drug-induced seizures
  10. Drug-induced syncope
  11. Neurological complications of general anesthesia
  12. Neurological complications of local anesthesia
  13. Serotonin syndrome
  14. Drug-induced sleep disorders

Alternative therapies in neurology

  1. Alternative methods for the treatment of neurological disorders
  2. Acupuncture and the neurologist
  3. Neurological complications of chiropractic manipulations
  4. Transcranial magnetic stimulation
  5. Hyperbaric oxygenation for treatment of stroke.

Molecular diagnostics

  1. Principles and methods of molecular diagnostics of neurologic disorders
  2. Molecular diagnosis of CNS malignancies
  3. Molecular diagnosis of infections of the CNS
  4. Molecular diagnosis of neurogenetic disorders

Neurogastroenterology

  1. Introduction to neurogastroenterology
  2. Neurological aspects of nausea and vomiting
  3. Dysphagia

Neurological disorders caused by changes in environments

  1. High pressure neurological syndrome
  2. Mountain sickness
  3. Carbon monoxide poisoning
  4. Neurologic complications of decompression

Miscellaneous topics in neurology, neurological syndromes

  1. Neurology of aging
  2. Impact of genomics on the practice of neurology
  3. Nutrition and the brain
  4. Vitamin E and neurological disorders
  5. Hepatic encephalopathy
  6. Multiple cranial nerve palsies
  7. Susac Syndrome
  8. Turcot syndrome
  9. Hiccup: Pathomechanisms and management
  10. Integration of diagnostics and therapeutics in the practice of neurology
  11. Gulf war syndrome
  12. Neuroproteomics
  13. Neurological aspects of chemical and biological warfare agents
  14. Neurological aspects of pathological laughter
  15. Nightmares
  16. Neurological causes and complications of fever
  17. Heat stroke
  18. Dysathria

Books

  1. Health Care in New China. Rodale Press, Emmaus, Pennsylvania, 1973.
  2. Handbook of Laser Neurosurgery. Charles C. Thomas, Springfield, Illinois, 1983.
  3. Handbook of Hyperbaric Oxygen Therapy. Springer-Verlag, New York, 1988.
  4. Oxygen in Physiology and Medicine. Charles C. Thomas, Springfield, 1989.
  5. Carbon Monoxide Poisoning, Warren H. Green, St. Louis, Missouri, 1990.
  6. Cerebral Insufficiency - pathophysiology and management. Year Book Publishers, Chicago, 1990.
  7. Textbook of Hyperbaric Medicine. Hogrefe & Huber, Goettingen, Germany, 5th edition, 2009.
  8. Drug-induced Neurological Disorders. Hogrefe & Huber, Goettingen, Germany, 3rd ed 2011 (in press).
  9. Textbook of Gene Therapy, Hogrefe & Huber, Goettingen, Germany, 1998 (Translated into Chinese edition 2000).
  10. Gene Therapy Companies, John Wiley & Sons, Chicester, UK, 2000 (updated version is included in the report on gene therapy 2011)
  11. Nanobiotechnology in Molecular Diagnostics. Horizon Scientific Press, Norwich, UK, 2006
  12. Jain KK (ed) Drug Delivery Systems.Humana/Springer, Totowa, NJ, 2008
  13. Handbook of Nanomedicine. Humana/Springer,Totowa, NJ, 2008 (translated for Chinese Edition 2011).
  14. Textbook of Personalized Medicine. Springer, New York, October 2009
  15. Jain KK (ed) Drug Delivery to the Central Nervous System. Humana/Springer, Totowa, NJ, Jan 2010
  16. The Handbook of Biomarkers. Springer,New York, 2010
  17. The Handbook of Neuroprotection. Springer, 2011.
  18. Application of Biotechnology in Cardiovascular Therapeutics. Springer, New York, 2011.

Reports

Published by PJB Publications, Richmond, UK

  1. Clinica Report on DNA Diagnostics, 1995.
  2. Scrip Report on Gene Therapy, 1995.
  3. Scrip Report on Ion Channels, 1995.
  4. Scrip Report on Vectors for Gene Therapy, 1996.
  5. Scrip Report on Antisense Therapy, 1996.
  6. Scrip Report on Cancer Gene Therapy, 1996.

Published by Decision Resources, Waltham, MA, USA

  1. Cognos Report on Parkinson's Disease, 1996.
  2. Gene Therapy of Neurological Disorders, 1997.
  3. Molecular Diagnostics, 1997.
  4. Personalized Medicines: The impact of pharmacogenetics on drug development, 1998.
  5. Drug Delivery Systems, 1998.
  6. Impact of Genomics on Drug Discovery and Development, 1999.
  7. Commercial Opportunities in Serotonin Modulating Drugs, 1999.
  8. Molecular Diagnostics II, 1999.
  9. Drug Delivery in CNS Diseases: Technologies and commercial opportunities, March 2000.
  10. Drug Delivery in Cancer: technologies and commercial opportunities, June 2000.

Published by International Business Communications (IBC)

  1. Jain KK (Ed), Proceedings of the Conference 'Gene to Screen', IBC, London, 1996.
  2. Strategies for Success in Biotechnology. D&MD Division, IBC, Southborough, Massachusetts, 1997.
  3. Stroke. D&MD, Division, IBC, Southborough, Massachusetts, 1998.

Published by Informa Global Pharmaceuticals & Healthcare, London.

  1. Drug Delivery Technologies. 2000.
  2. Biochips. 2000.
  3. Drug Discovery: current trends and future prospects. 2001.
  4. Ageing: biology, healthcare and pharmaceutical opportunities. 2001.
  5. Personalized Medicine. 2001.

Miscellaneous Publishers

  1. Jain KK, Tool JF (Eds) Hyperacute Hyperbaric Oxygen Therapy for Stroke: Proceedings of a Conference held at Bowman Gray School of Medicine, Winston-Salem, North Carolina, 2-4 Nov 1997. Undersea & Hyperbaric Medical Society of the USA, Bethesda, Maryland, 1998.
  2. Antisense Technologies: commercial opportunities, Reuters Business Insight, UK, 2000.
  3. Pain therapeutics: re-evaluation of strategies, Reuters Business Insight, UK, 2000.

Published by Jain PharmaBiotech, Basel, Switzerland.

  1. Neurotrophic Factors - Current Status and Future Potential. Published in 1996. Revised 2000.
  2. Neuroprotection - Drugs, Companies and Markets. 2012.
  3. Proteomics - Technologies, Companies and Markets. 2012.
  4. Cell Therapy - Technologies, Companies and Markets. 2012.
  5. Molecular diagnostics - Technologies, Companies and Markets. 2012.
  6. Transdermal Drug Delivery - Technologies, Companies and Markets. 2012.
  7. Animal Biotechnology - Technologies, Companies and Markets. 2012.
  8. Pain Therapeutics - drugs, companies and markets. 2012.
  9. Personalized Medicine - scientific and commercial aspects. 2012.
  10. Nitric Oxide - therapeutics, markets and companies. 2012.
  11. Alzheimer disease - new drugs, markets and companies. 2012.
  12. Drug Delivery in Cancer - technologies, markets and companies. 2012.
  13. RNAi - technologies, markets and companies. 2012.
  14. Gene Therapy - technologies, markets and companies. 2012.
  15. Nanobiotechnology - applications, markets and companies. 2012.
  16. Drug Delivery in Central Nervous System Disorders - technologies, markets and companies. 2012.
  17. Cardiovascular Drug Delivery - technologies, markets and companies. 2012.
  18. Biomarkers - technologies, markets and companies. 2012.
  19. Cytogenetics - technologies, markets and companies. 2012.
  20. Antiviral Therapeutics - technologies, markets and companies. 2012.
  21. DNA Sequencing - technologies, markets and companies. 2012.
  22. Biochips/Microarrays - technologies, markets and companies. 2012.
  23. Therapeutic Drug Monitoring - technologies, markets and companies. 2012.